Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
CLOPAMON®-T TABLETS CLOPAMON®-S SYRUP CLOPAMON® SUPPOSITORIES 5 mg CLOPAMON® SUPPOSITORIES 10 mg SCHDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CLOPAMON ® -T TABLETS CLOPAMON ® -S SYRUP CLOPAMON ® SUPPOSITORIES 5 mg CLOPAMON ® SUPPOSITORIES 10 mg COMPOSITION: Tablets Contains 10 mg metoclopramide monohydrochloride. Syrup Contains 5 mg/5 mL metoclopramide monohydrochloride Preservatives: Methyl p-hydroxybenzoate B.P. 0,08 % m/v. Propyl p-hydroxybenzoate B.P. 0,02 % m/v. Suppositories: Contains 5 mg or 10 mg metoclopramide free base. PHARMACOLOGICAL CLASSIFICATION: A 5.7.2. Anti-emetics and antivertigo preparations. PHARMACOLOGICAL ACTION: Gastro-intestinal Action: Metoclopramide increases the number, mean strength and total activity of gastric antral contractions and also produces a significant increase in the strength of duodenal contractions, which decreases intestinal transit time. These changes would all tend to increase the speed of gastric emptying, which has been observed radiologically and by other methods. Metoclopramide has no effect on gastric secretion or on the cardiovascular system. Metoclopramide has an effect on the gastro-oesophageal junction of the stomach, producing an increase in cardiac sphincter pressure. The increase in pressure seen, after metoclopramide is administered, is directly proportional to the initial resting pressure, and minimal or absent in those with very low resting pressures. The action of metoclopramide on the gastro-intestinal tract is antagonised by atropine and other anticholinergic medicines if they are administered in the previous 3 hours. Anti-Emetic Action: Metoclopramide acts on the chemo-emetic trigger zone to produce a central anti-emetic effect. The anti-emetic action of metoclopramide is not affected by atropine and other Read the complete document